BiotechTube

M5049 high dose + Placebo

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dermatomyositis

Conditions

Dermatomyositis, Polymyositis

Trial Timeline

Jan 19, 2023 → Jun 25, 2025

NCT ID
NCT05650567

About M5049 high dose + Placebo

M5049 high dose + Placebo is a phase 2 stage product being developed by Merck for Dermatomyositis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05650567. Target conditions include Dermatomyositis, Polymyositis.

What happened to similar drugs?

0 of 3 similar drugs in Dermatomyositis were approved

Approved (0) Terminated (1) Active (2)
🔄DazukibartPfizerPhase 3
❌human immunoglobulin G + PlaceboCSLPhase 3
🔄Lenabasum 20 mg + Lenabasum 5 mg + PlaceboCorbus PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05650567Phase 2Terminated

Competing Products

14 competing products in Dermatomyositis

See all competitors
ProductCompanyStageHype Score
tacrolimusAstellas PharmaPre-clinical
26
BAF312 + PlaceboNovartisPhase 2
27
MEDI7734 + PlaceboAmgenPhase 1
29
Etanercept + PlaceboAmgenPhase 1
29
DazukibartPfizerPhase 3
47
Anti-Beta Interferon (PF-06823859)PfizerPhase 2
35
PF-06823859 low + Placebo Arm + PF-06823859 highPfizerPhase 2
35
TofacitinibPfizerPhase 1
29
EmapalumabSwedish Orphan BiovitrumPhase 2
42
human immunoglobulin G + PlaceboCSLPhase 3
32
Empasiprubart IVArgenxPhase 2
36
GLPG3667 + PlaceboGalapagosPhase 2
33
Lenabasum 20 mg + Lenabasum 5 mg + PlaceboCorbus PharmaceuticalsPhase 3
30
JBT-101 + PlaceboCorbus PharmaceuticalsPhase 2
17